Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Intangibles (2016 - 2024)

Historic Intangibles for Trinity Biotech (TRIB) over the last 10 years, with Q4 2024 value amounting to $51.3 million.

  • Trinity Biotech's Intangibles rose 21556.85% to $51.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $51.3 million, marking a year-over-year increase of 21556.85%. This contributed to the annual value of $51.3 million for FY2024, which is 21556.85% up from last year.
  • According to the latest figures from Q4 2024, Trinity Biotech's Intangibles is $51.3 million, which was up 21556.85% from $16.3 million recorded in Q4 2023.
  • Over the past 5 years, Trinity Biotech's Intangibles peaked at $51.3 million during Q4 2024, and registered a low of $16.3 million during Q4 2023.
  • Over the past 5 years, Trinity Biotech's median Intangibles value was $35.3 million (recorded in 2022), while the average stood at $34.5 million.
  • Its Intangibles has fluctuated over the past 5 years, first tumbled by 5386.88% in 2023, then surged by 21556.85% in 2024.
  • Over the past 5 years, Trinity Biotech's Intangibles (Quarter) stood at $33.9 million in 2020, then increased by 6.26% to $36.0 million in 2021, then fell by 1.98% to $35.3 million in 2022, then plummeted by 53.87% to $16.3 million in 2023, then soared by 215.57% to $51.3 million in 2024.
  • Its last three reported values are $51.3 million in Q4 2024, $16.3 million for Q4 2023, and $35.3 million during Q4 2022.